← All stocks

Replimune Group, Inc.

REPL Net selling

CIK 0001737953 #2319 in the set updated 18 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$1.93M

$274.25K on a plan · $32.96K straight out of an exercise

Sold at will

$1.63M

13 of 17 sales

Net

−$1.93M

−$1.63M against sales at will

By person

7 insiders · 17 transactions

14.4×

Sushil Patel holds 14.4 times base salary in stock. $10.11M of shares against $700.00K in salary for 2026.

Salary from the company's own proxy. The shares are what Sushil Patel last reported holding, valued at $14.28, the price Common Stock was last bought or sold at on the open market here, on 17 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Patel Sushil

Chief Executive Officer

—

$811.16K (3)

−$811.16K

708,151

0.8436%

$10.11M

+234.0%

Hill Emily Luisa

Chief Financial Officer

—

$320.34K (3)

−$320.34K

215,852

0.2571%

$3.08M

+113.6%

Xynos Konstantinos

Chief Medical Officer

—

$285.66K (3)

−$285.66K

224,215

0.2671%

$3.20M

+91.4%

Sarchi Christopher

Chief Commercial Officer

—

$254.16K (4) scheduled

−$254.16K

180,962

0.2156%

$2.58M

+96.2%

Schwendenman Andrew

Chief Accounting Officer

—

$139.09K (2)

−$139.09K

99,425

0.1184%

$1.42M

−44.2%

Astley-Sparke Philip

Director

—

$89.70K (1)

−$89.70K

1,362,414

1.62%

$19.46M

−5.2%

Dhingra Kapil

Director

—

$32.96K (1) scheduled

−$32.96K

0.0000%

$0.00

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Sarchi Christopher

1 Jun 2026

Chief Commercial Officer

Sold on a plan

12,000

$9.24

$110.88K

Sarchi Christopher

2 Apr 2026

Chief Commercial Officer

Sold on a plan

6,500

$8.01

$52.07K

Patel Sushil

2 Dec 2025

Chief Executive Officer

Sold on a plan

10,000

$11.13

$111.30K

Show all 17 transactions →

What was left out

Form 4 filings counted 39

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 2

Sales on a Rule 10b5-1 plan 3

Sales straight out of an exercise 1

Sales at will 13

Transactions with no price 0

Shares from compensation/vesting 931,076

History held since 25 Jul 2018